000086389 001__ 86389
000086389 005__ 20200716101601.0
000086389 0247_ $$2doi$$a10.3390/cancers11060780
000086389 0248_ $$2sideral$$a115081
000086389 037__ $$aART-2019-115081
000086389 041__ $$aeng
000086389 100__ $$aMármol, Inés$$uUniversidad de Zaragoza
000086389 245__ $$aGold as a possible alternative to platinum-based chemotherapy for colon cancer treatment
000086389 260__ $$c2019
000086389 5060_ $$aAccess copy available to the general public$$fUnrestricted
000086389 5203_ $$aDue to the increasing incidence and high mortality associated with colorectal cancer (CRC), novel therapeutic strategies are urgently needed. Classic chemotherapy against CRC is based on oxaliplatin and other cisplatin analogues; however, platinum-based therapy lacks selectivity to cancer cells and leads to deleterious side effects. In addition, tumor resistance to oxaliplatin is related to chemotherapy failure. Gold(I) derivatives are a promising alternative to platinum complexes, since instead of interacting with DNA, they target proteins overexpressed on tumor cells, thus leading to less side effects than, but a comparable antitumor effect to, platinum derivatives. Moreover, given the huge potential of gold nanoparticles, the role of gold in CRC chemotherapy is not limited to gold(I) complexes. Gold nanoparticles have been found to be able to overcome multidrug resistance along with reduced side effects due to a more efficient uptake of classic drugs. Moreover, the use of gold nanoparticles has enhanced the effect of traditional therapies such as radiotherapy, photothermal therapy, or photodynamic therapy, and has displayed a potential role in diagnosis as a consequence of their optic properties. Herein, we have reviewed the most recent advances in the use of gold(I) derivatives and gold nanoparticles in CRC therapy.
000086389 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B16-R17$$9info:eu-repo/grantAgreement/ES/DGA/E07-17R$$9info:eu-repo/grantAgreement/ES/MINECO/CTQ2016-75816-C2-1-P$$9info:eu-repo/grantAgreement/ES/MINECO/SAF2016-75441-R
000086389 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000086389 590__ $$a6.126$$b2019
000086389 591__ $$aONCOLOGY$$b37 / 244 = 0.152$$c2019$$dQ1$$eT1
000086389 592__ $$a1.938$$b2019
000086389 593__ $$aOncology$$c2019$$dQ1
000086389 593__ $$aCancer Research$$c2019$$dQ1
000086389 655_4 $$ainfo:eu-repo/semantics/review$$vinfo:eu-repo/semantics/publishedVersion
000086389 700__ $$aQuero, Javier
000086389 700__ $$0(orcid)0000-0002-3595-7668$$aRodríguez-Yoldi, María Jesús$$uUniversidad de Zaragoza
000086389 700__ $$0(orcid)0000-0003-2457-3674$$aCerrada, Elena$$uUniversidad de Zaragoza
000086389 7102_ $$12010$$2760$$aUniversidad de Zaragoza$$bDpto. Química Inorgánica$$cÁrea Química Inorgánica
000086389 7102_ $$11005$$2410$$aUniversidad de Zaragoza$$bDpto. Farmacología y Fisiolog.$$cÁrea Fisiología
000086389 773__ $$g11, 6 (2019), 780 [36 pp.]$$pCancers$$tCancers$$x2072-6694
000086389 8564_ $$s929525$$uhttps://zaguan.unizar.es/record/86389/files/texto_completo.pdf$$yVersión publicada
000086389 8564_ $$s107859$$uhttps://zaguan.unizar.es/record/86389/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000086389 909CO $$ooai:zaguan.unizar.es:86389$$particulos$$pdriver
000086389 951__ $$a2020-07-16-09:53:00
000086389 980__ $$aARTICLE